What did H.C. Wainwright do for Ligand on February 24, 2026?

H.C. Wainwright maintained a **Buy** rating and raised the price target to **$239** from **$231** on February 24, 2026, a move that signals continued analyst confidence.

How should investors interpret the LGND analyst rating maintained at Buy?

A maintained Buy signals the analyst still expects upside versus current levels, but investors should combine this view with financials, partner revenue timing, and pipeline catalysts before adjusting positions.

Does the updated price target change the stock outlook materially?

The **$8** increase in the LGND price target is modest and represents a tactical valuation tweak rather than a major outlook change; monitor future notes for stronger guidance.

What is Meyka AI’s current grade for LGND and what it means?

Meyka AI rates LGND with a grade of **B+**, reflecting relative benchmark performance, sector factors, growth metrics, and analyst consensus; grades are informational and not investment advice.

Analyst Ratings

H.C. Wainwright Maintained Buy on Ligand (LGND) Feb 24, 2026

ByHuzaifa Zahoor February 25, 2026February 25, 2026

H.C. Wainwright on February 24, 2026 maintained a Buy on Ligand Pharmaceuticals Incorporated (LGND) and raised its price target to $239 from $231. The LGND analyst rating remains positive and signals continued confidence from a notable biotech specialist. The firm logged a modest market reaction of 0.45% ($0.84) move on the news. With a market capitalization of $3,719,845,080, this maintained Buy and higher price target provide a clear near-term directional cue for investors.